pembrolizumab

Pembrolizumab is a medication that targets PD-1 protein to enhance immune responses against cancer cells. It has been approved for use in several types of cancer, including ovarian cancer and is being rolled out in the NHS in England. Recent news highlights its potential benefits for thousands of patients annually. The drug's repurposed origin from treating a rare disease adds to its significance. Its approval and rollout demonstrate growing interest in immunotherapy treatments for various cancers, offering new hope for patients with aggressive forms of ovarian cancer and other conditions.